UK firm PsiOxus starts clinical trial with cancer gene therapy NG-641
PsiOxus initiated a clinical trial with NG-641 to treat people with cancer. Credit: Dr. Cecil Fox.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.ContinueLearn more
